Real-life studies in allergen immunotherapy
暂无分享,去创建一个
[1] Kevin Crosby,et al. Copyright 2021 , 2021, 2021 25th International Computer Science and Engineering Conference (ICSEC).
[2] C. Escudero,et al. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: A retrospective, controlled real-world study☆ , 2020, The World Allergy Organization journal.
[3] P. Demoly,et al. Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies? , 2020, Expert review of respiratory medicine.
[4] G. Passalacqua,et al. Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study , 2020, BioMed research international.
[5] G. Passalacqua,et al. Biologicals for severe asthma: what we can learn from real-life experiences? , 2020, Current opinion in allergy and clinical immunology.
[6] Derya Ünal,et al. Effects of Perennial Allergen Immunotherapy in Allergic Rhinitis in Patients with/without Asthma: A-Randomized Controlled Real-Life Study , 2020, International Archives of Allergy and Immunology.
[7] Y. Nam,et al. Efficacy of Allergen Immunotherapy for Allergic Asthma in Real World Practice , 2019, Allergy, asthma & immunology research.
[8] P. Demoly,et al. Contraindications to immunotherapy: a global approach , 2019, Clinical and Translational Allergy.
[9] A. Sheikh,et al. Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases , 2019, Clinical and Translational Allergy.
[10] N. Papadopoulos,et al. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group , 2019, European Respiratory Journal.
[11] A. Sheikh,et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. , 2019, The Journal of allergy and clinical immunology.
[12] D. Golden,et al. Real-life safety of 5-grass pollen tablet in 5-to-9-year-old children with allergic rhinoconjunctivitis. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[13] P. Demoly,et al. Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France , 2019, Allergy.
[14] G. Canonica,et al. The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials , 2018, The World Allergy Organization journal.
[15] Kamlesh Khunti,et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.
[16] C. Bachert,et al. Real‐world benefits of allergen immunotherapy for birch pollen‐associated allergic rhinitis and asthma , 2018, Allergy.
[17] J. Gagne,et al. Using Real‐World Data to Extrapolate Evidence From Randomized Controlled Trials , 2018, Clinical pharmacology and therapeutics.
[18] D. Larenas-Linnemann,et al. What you should not miss from the systematic reviews and meta-analyses on allergen-specific immunotherapy in 2017 , 2018, Current opinion in allergy and clinical immunology.
[19] S. Durham,et al. Practice and safety of allergen‐specific immunotherapy for allergic rhinitis in the UK national health service: A report of “real world” clinical practice , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[20] P. Devillier,et al. Sublingual immunotherapy provides long‐term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real‐world database analysis , 2017, Allergy.
[21] P. Demoly,et al. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real‐life clinical assessment , 2017, Allergy.
[22] E. Valovirta,et al. Real‐life safety of allergen immunotherapy in children and adolescents , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[23] P. Demoly,et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment , 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.
[24] C. Incorvaia,et al. Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment. , 2016, European annals of allergy and clinical immunology.
[25] Tomić Vesna,et al. Efficacy of Sublingual Immunotherapy with Dermatophagoides Pteronyssinus: A Real-life Study. , 2016, Iranian journal of allergy, asthma, and immunology.
[26] J. Schmitt,et al. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: Results from a large retrospective cohort study. , 2015, The Journal of allergy and clinical immunology.
[27] C. Bachert,et al. Allergen immunotherapy on the way to product-based evaluation—a WAO statement , 2015, The World Allergy Organization journal.
[28] M. Caminati,et al. Omalizumab management beyond clinical trials: the added value of a network model. , 2014, Pulmonary pharmacology & therapeutics.
[29] P. Demoly,et al. An EAACI “European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)”: the methodology , 2014, Clinical and Translational Allergy.
[30] N. Scichilone,et al. Randomized Controlled Trials and real life studies. Approaches and methodologies: a clinical point of view. , 2014, Pulmonary Pharmacology & Therapeutics.
[31] W. Shaikh,et al. A prospective study on the safety of sublingual immunotherapy in pregnancy , 2012, Allergy.
[32] P. Howarth,et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA‐GA2LEN statement , 2011, Allergy.
[33] E. Magen,et al. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life. , 2008, The Israel Medical Association journal : IMAJ.
[34] M Landi,et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children , 2008, Allergy.
[35] H. Schünemann,et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. , 2011, The Journal of allergy and clinical immunology.
[36] O. Skjønsberg,et al. How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? , 2005, Respiratory medicine.
[37] L. Levi. Stress and distress in response to psychosocial stimuli. Laboratory and real life studies on sympathoadrenomedullary and related reactions. , 1972, Acta medica Scandinavica. Supplementum.